<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02445859</url>
  </required_header>
  <id_info>
    <org_study_id>MB15/130</org_study_id>
    <nct_id>NCT02445859</nct_id>
  </id_info>
  <brief_title>Continuous Antibiotic Prophylaxis in Colorectal Surgery</brief_title>
  <acronym>Colo-Pro</acronym>
  <official_title>Colo-Pro Pilot: A Pilot Study to Compare Standard Single Dose Antibiotic Prophylaxis to Bolus-continuous Infusion Dosed Antibiotic Prophylaxis for the Prevention of Infections After Colorectal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leeds</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Leeds</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We propose to randomise patients due to undergo colorectal surgery to standard antibiotic
      prophylaxis or an interventional antibiotic prophylaxis regimen and assess surgical wound
      infection rates. Standard antibiotic prophylaxis is a pre-operative injection of cefuroxime,
      repeated every 4 hours. The intervention regimen is a loading dose of cefuroxime followed by
      a continuous infusion of cefuroxime until the end of surgery. The intervention regimen dosing
      will be calculated using a patient's renal function and body weight. The intervention regimen
      will target a free serum drug concentration of 64mg/L. This serum level is 4x the MIC90 for
      colonising Enterobacteriaceae. The rational for this dosing regimen is summarised below. The
      primary objective of the study is to reduce by 50% the rate of surgical wound infections
      after colorectal surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An expert assessment is that fT&gt;MIC is the measure most likely to be applicable to
      prophylaxis. But this measure is not achieved by standard prophylaxis regimens. Neither do
      clinical data suggest this target achieves optimal prophylaxis. Therefore there is an
      opportunity to optimise antibiotic prophylaxis dosing. As the exposure response-relationship
      (pharmacodynamic target) is unknown we could either complete a number of studies exploring
      different relationships, or compare standard treatment to a single regimen which included a
      number of exposure-response relationships. The two most common exposure-response
      relationships are the CMAX/MIC ratio and the fT&gt;MIC. And it has been reported that killing,
      as opposed to inhibition used in MIC values, is optimised by achieving 4 times an MIC value.
      An antibiotic prophylaxis regimen which achieved drug concentrations of 4xMIC for the
      duration of surgery would therefore achieves a high CMAX/MIC ratio, high T&gt;MIC, and optimise
      bacterial killing. Therefore, standard dose antibiotic prophylaxis will be compared against a
      PD target dosed antibiotic prophylaxis regimen. The PD target will be a free serum antibiotic
      concentration of 4xMIC90 for Enterobacteriaceae against cefuroxime. Continuous infusion of
      antibiotic prophylaxis will ensure there is continuous targeting of this drug level
      throughout the operation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With a Surgical Site Infection</measure>
    <time_frame>Number of patients with a surgical site infection within 30 days of a colorectal surgical procedure.</time_frame>
    <description>Superficial and deep surgical site infections as defined by the CDC (Centre's for Disease Control) definitions of surgical site infections.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Surgical Site Infection</condition>
  <arm_group>
    <arm_group_label>Standard regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cefuroxime 1.5grams pre-operatively Repeated every 4 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interventional regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cefuroxime continuous infusion targeting 64mg/l serum concentrations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefuroxime 4 hourly bolus</intervention_name>
    <description>Cefuroxime loading dose followed by a continuous infusion dosed according to renal function. Dosed to target a serum concentration of 64mg/L.</description>
    <arm_group_label>Interventional regimen</arm_group_label>
    <arm_group_label>Standard regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Undergoing colorectal surgery (incision, excision or anastomosis of the large bowel,
             including anastomosis of small to large bowel)

          -  Age &gt;18.

          -  Expected duration of surgery &gt; 2hours

          -  Creatinine clearance &gt; 40 ml/min

          -  Cefuroxime/metronidazole are appropriate antibiotic prophylaxis regimens.

          -  Patient capable of giving informed consent

          -  Patients undergoing colorectal surgery plus additional surgery e.g. plastic surgery,
             urological surgery, gynaecological surgery.

          -  If it is not possible to obtain intra-operative blood samples e.g. difficult vascular
             access, or pre-operative swabs e.g. anatomy makes it difficult to obtain, patients
             will be included and this information treated as missing data. Patients on antibiotic
             treatment for an existing infection (except SSIs) can be included in the study

        Exclusion Criteria:

          -  Unable to consent

          -  Pregnancy

          -  Expected duration of surgery &lt;2hours

          -  Creatinine clearance &lt;40ml/min

          -  Individual level microbiological advice for non cefuroxime based prophylaxis

          -  Cephalosporin allergy

          -  Penicillin allergy (hypersensitivity reaction only)

          -  Coumarin (warfarin and acenocoumarol) treatment

          -  Active blood borne virus infection e.g. HIV, hepatitis.

          -  Seizure history

          -  Concurrent use of probenecid

          -  Current participation in a research project aimed at reducing SSIs

          -  Antibiotics for treatment of a systemic Gram negative infection within 2 hours of
             initiation of surgery (Vancomycin, Teicoplanin, Daptomycin, Linezolid, Flucloxacillin.
             Nitrofurantoin and Clarithromycin would be permissible antibiotics without systemic
             Gram negative antibiotics).

          -  A current diagnosis of a SSI at the time of study entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Kirby</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Leeds</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS Trust</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>May 13, 2015</study_first_submitted>
  <study_first_submitted_qc>May 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2015</study_first_posted>
  <results_first_submitted>June 3, 2019</results_first_submitted>
  <results_first_submitted_qc>August 7, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 12, 2019</results_first_posted>
  <last_update_submitted>October 8, 2019</last_update_submitted>
  <last_update_submitted_qc>October 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Leeds</investigator_affiliation>
    <investigator_full_name>Andrew Kirby</investigator_full_name>
    <investigator_title>Associate clinical professor</investigator_title>
  </responsible_party>
  <keyword>Antibiotic</keyword>
  <keyword>prophylaxis</keyword>
  <keyword>surgical site infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Surgical Wound Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cefuroxime</mesh_term>
    <mesh_term>Cefuroxime axetil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 10, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT02445859/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 24, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT02445859/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard Regimen</title>
          <description>Cefuroxime 1.5grams pre-operatively Repeated every 4 hours
Cefuroxime bolus-continuous infusion: Cefuroxime 1.5 grams pre-operatively, repeated 4 hourly during surgery.</description>
        </group>
        <group group_id="P2">
          <title>Interventional Regimen</title>
          <description>Cefuroxime continuous infusion targeting 64mg/l serum concentrations.
Cefuroxime 4 hourly bolus: Cefuroxime loading dose followed by a continuous infusion dosed according to renal function. Dosed to target a serum concentration of 64mg/L.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The analysis population was on an intention to treat basis</population>
      <group_list>
        <group group_id="B1">
          <title>Standard Dosing</title>
          <description>Intravenous (IV) cefuroxime 1.5g bolus administered four-hourly throughout surgery</description>
        </group>
        <group group_id="B2">
          <title>Intervention Dosing</title>
          <description>Cefuroxime bolus-continuous dosing was based on targeting non-protein bound (free) serum concentrations of antibiotic at 64mg/L throughout surgery</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Collection by review of medical records</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="45"/>
                    <count group_id="B2" value="45"/>
                    <count group_id="B3" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="17"/>
                    <measurement group_id="B2" value="61" spread="17"/>
                    <measurement group_id="B3" value="60" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Collection by review of medical records</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="45"/>
                    <count group_id="B2" value="45"/>
                    <count group_id="B3" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With a Surgical Site Infection</title>
        <description>Superficial and deep surgical site infections as defined by the CDC (Centre's for Disease Control) definitions of surgical site infections.</description>
        <time_frame>Number of patients with a surgical site infection within 30 days of a colorectal surgical procedure.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Regimen</title>
            <description>Cefuroxime 1.5grams pre-operatively Repeated every 4 hours
Cefuroxime bolus-continuous infusion: Cefuroxime 1.5 grams pre-operatively, repeated 4 hourly during surgery.</description>
          </group>
          <group group_id="O2">
            <title>Interventional Regimen</title>
            <description>Cefuroxime continuous infusion targeting 64mg/l serum concentrations.
Cefuroxime 4 hourly bolus: Cefuroxime loading dose followed by a continuous infusion dosed according to renal function. Dosed to target a serum concentration of 64mg/L.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With a Surgical Site Infection</title>
          <description>Superficial and deep surgical site infections as defined by the CDC (Centre's for Disease Control) definitions of surgical site infections.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Standard Regimen</title>
          <description>Cefuroxime 1.5grams pre-operatively Repeated every 4 hours
Cefuroxime bolus-continuous infusion: Cefuroxime 1.5 grams pre-operatively, repeated 4 hourly during surgery.</description>
        </group>
        <group group_id="E2">
          <title>Interventional Regimen</title>
          <description>Cefuroxime continuous infusion targeting 64mg/l serum concentrations.
Cefuroxime 4 hourly bolus: Cefuroxime loading dose followed by a continuous infusion dosed according to renal function. Dosed to target a serum concentration of 64mg/L.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anastomotic leak</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Unplanned surgical procedure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Gastrointestinal bleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Pleural effusion with pleural drain insertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>These patients are expected to have multiple adverse events. We only formally collected all serious adverse events, plus specific events e.g. C.difficile. As a pilot trial we have learned about the collection of adverse events in this patient group.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Andrew Kirby</name_or_title>
      <organization>The Universit yof Leeds</organization>
      <phone>0044 113 3923989</phone>
      <email>a.kirby@leeds.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

